StockArkalytics.com
The Heat Sheet
April 7, 2026 · 17 Tickers · 5 Themes
You're reading a free issue of The Heat Sheet
Get it in your inbox every week — AI-powered signals, volume leaders, unusual options flow.
🔥 Weekly Scanner — Volume Leaders · 30-Day Window
5 Themes. 17 Tickers.
The Market Is Screaming.
This isn't noise. The names hitting our scanner this cycle share something the headlines keep missing: every single one maps to a structural macro shift. AI photonics. Orbital infrastructure. Autonomous defense. RAS cancer biology. Geopolitical commodity squeezes. We broke it into 5 themes — and went deep on all 17.
SCANNER FREQUENCY — 30 DAYS
Every name on this list cleared our scanner at least 7 times in 30 days. That's not a coincidence — it's a pattern. And when we ran the themes, it became clear: institutional hands are working five plays simultaneously. Let's break down each one.
📬 Get This In Your Inbox Every Week — Free
The Heat Sheet drops every Monday morning.
Volume leaders · Unusual options flow · AI-powered deep analysis. No spam.
Free plan available · See plans
Theme 01 · 4 Tickers
🔦 Photon Rush
The AI backbone debate has fixated on GPUs. But you can't move data between 100,000 GPUs using copper. You need light. The photonics and optical transceiver market is in a multi-year structural upcycle — and NVIDIA, Microsoft, and Amazon are signing the checks. Every name in this bucket is tied directly to 1.6T transceiver demand or the compound semiconductor substrate supply chain that enables it.
Lumentum is the most institutionally loaded name in AI photonics right now. NVIDIA just committed a $2 billion direct investment to secure dedicated capacity in Lumentum's electro-absorption modulated lasers (EMLs) — the core component in 1.6T and 3.2T transceivers. Management unveiled a "2028 North Star" model at March's Optical Fiber Communication Conference targeting $30+ EPS annualized, anchored by quarterly revenue run-rates hitting $2B within 24 months. LITE was added to the S&P 500 in early March, triggering mechanical index buying. Mizuho picked it as a top AI chip stock for 2026 alongside NVDA and AVGO. The backlog for optical circuit switching systems alone exceeds $400M. This is no longer a telecom equipment name — it's a critical AI infrastructure play.
AI Photonics · 1.6T Transceivers · NVIDIA Partnership · S&P 500 · Infrastructure Tier 1
👥 Who's watching: Large-cap tech funds, AI infrastructure ETFs, semiconductor income plays — this is the name institutions add when they want optical exposure with a defensible moat.
VERDICT
The most de-risked way to own the photonics trade. S&P inclusion provides passive floor. NVIDIA's $2B commitment removes demand uncertainty through at least 2027. The only risk: manufacturing yields at the new Greensboro fab. Watch those quarterly numbers closely.
AAOI is the highest-velocity name in this cluster. Q4 2025 revenue hit a record $134.27M, up 33.9% year-over-year, beating EPS estimates by over 90%. Then in March, the company announced its first volume order for 1.6T data center transceivers from a major hyperscale — a $200M+ contract. Q1 2026 guidance was $150M–$165M, with full-year 2026 revenue potentially exceeding $1 billion. Management is projecting monthly transceiver revenue of $378M by mid-2027 — a near-10x demand surge in 18 months. Microsoft is the largest current customer; Amazon is ramping 400G and 800G adoption. AAOI is up 173%+ YTD as of early March and surged 15% on contract announcement day. This is not a slow-money play.
1.6T Transceivers · Record Revenue · Hyperscale Customer · High Velocity · Momentum
👥 Who's watching: Momentum traders, options flow players, and any fund with a hyperscaler supply-chain thesis. Note: CEO sold shares in January 2026 — worth watching on the insider tape.
🔥 HOT TAKE
If AAOI executes on the $1B 2026 guide, this stock isn't done. But with 173% already in the tank and a volatile sector subject to rotation, the risk/reward window narrows fast. Position sizing matters more than entry here.
Ciena is the steady compounder of this group — up 351% over the past year, and still showing institutional accumulation. CEO Gary Smith described current conditions as "unprecedented, broad-based demand" as cloud providers monetize their AI investments. Q1 FY2026 saw Direct Cloud Provider revenue jump 76% year-over-year, representing 42% of total revenue. Ciena has secured wins with three of the four major cloud operators for wide-area "scale-across" networking projects linking AI data centers. Full-year guidance raised to $5.9B–$6.3B. The optical networking layer connecting AI clusters is CIEN's bread and butter — and those clusters aren't slowing down.
Wide-Area Networking · Cloud Provider Revenue · AI Data Center Backbone · Guidance Raise · Slow Compounder
👥 Who's watching: Value-growth crossover funds and long-duration tech investors who want optical exposure with a revenue line, not just a product roadmap.
AXTI is the supply chain bet in the photonics stack — the substrate maker, not the transceiver assembler. AXT manufactures indium phosphide (InP), gallium arsenide (GaAs), and germanium wafers — the raw material that goes into every high-speed optical component. The stock is up 465%+ since November 2025 as the indium phosphide market awakens to AI data center demand. In December, the company raised $100M in a public offering, earmarked to double InP manufacturing capacity in 2026. New customers in the transceiver segment broadened the base significantly. The risk: AXT is still operating at negative EBIT margin, and insider selling has been notable. But the structural thesis — compound semiconductors are the picks-and-shovels play of the photonics boom — is sound.
Indium Phosphide · Compound Semiconductors · Supply Chain Play · Capacity Expansion · High Beta
👥 Who's watching: Speculative growth traders and thematic ETF managers running AI-infrastructure supply chain themes. Watch the insider tape carefully here.
🔥 PHOTON RUSH — THEME HOT TAKE
The fiber boom of 1999 ended in tears because demand was speculative. This time, every 1.6T module rolling off the line is pre-allocated to a GPU cluster already under construction. That distinction matters. LITE and CIEN are the compounders. AAOI is the momentum trade. AXTI is the picks-and-shovels spec. Know which one you're owning before you buy any of them.
Theme 02 · 6 Tickers
🚀 Orbital Economy
The space trade isn't just about rockets anymore. Three simultaneous catalysts are fueling it: SpaceX IPO buzz ($75B valuation floated, biggest IPO ever projected), NASA's $20 billion "Ignition" moon base initiative through 2032, and DoD proliferated orbit defense contracts. Six names hit our scanner in this window. We break down who's a legitimate infrastructure play and who's riding the momentum coat-tails.
AST SpaceMobile is building the first space-based cellular broadband network accessible directly from standard smartphones — no special hardware required. The total addressable market is extraordinary: agreements with 50+ mobile network operators covering nearly 3 billion subscribers, including AT&T, Verizon, Vodafone, and Orange. The BlueBird 6 satellite launched in early 2026 became the largest commercial communications array ever deployed in LEO, 3x larger than previous BlueBirds. 2025 revenue was $70.9M — proving it is no longer pre-revenue. ASTS joined the MSCI World Index in February 2026. The headwind: a $1B convertible note offering triggered a 15% single-day drop, and B. Riley downgraded to Neutral while raising target to $105.
Direct-to-Cell Satellite · 3B Addressable Subscribers · BlueBird LEO · Verizon Partnership · MSCI World
👥 Who's watching: High-risk growth funds, space-themed ETFs, and retail momentum traders on r/wallstreetbets. The dilution risk from the convertible note is real — factor it into position sizing.
Intuitive Machines won the $4.8B NASA Near Space Network contract — the communications backbone between Earth and the moon under the Artemis program. The company also acquired Lanteris Space Systems for $800M, completed in Q1 2026, and secured an Air Force Research Laboratory contract shortly after. Management positioned the combined entity as a "next generation space prime." Current backlog: $235.9M. Cash position: $622M. Deutsche Bank named LUNR a top idea tied to America's return to the moon. The IM-2 lunar mission is a binary catalyst event in 2026: success = massive momentum, failure = significant drawdown.
NASA Prime Contractor · Lunar Commerce · $4.8B Network Contract · Artemis Program · M&A Expansion
👥 Who's watching: Defense-adjacent growth funds and space economy thematic players. This is the most commercially grounded lunar play available publicly.
Planet Labs operates the world's largest constellation of Earth-imaging satellites, providing daily global coverage for government, agriculture, defense, and commercial customers. The geospatial intelligence market is expanding fast as both national security agencies and commercial firms demand real-time satellite imagery for supply chain monitoring, climate tracking, and conflict intelligence. PL has been volatile — down 3%+ in early February as risk-off sentiment swept space stocks — but the fundamental case around real-time geospatial data as a recurring revenue model hasn't broken. The upcoming earnings and any defense contract announcements are key catalysts to watch.
Geospatial Intelligence · Daily Global Imagery · Defense Data · SaaS Revenue Model · Volatile
👥 Who's watching: GovTech and national security investors, plus ESG-adjacent funds tracking climate and agricultural data applications.
York Space Systems went public in January 2026 at $38/share — with the CEO specifically touting the company's "Golden Dome" defense potential on CNBC at debut. YSS is a space and defense prime providing spacecraft and mission solutions for national security and government customers. The company saw a new analyst rating in late March, and earnings call signals pointed to a growth pivot. The stock hit an all-time high of $38.47 at IPO, dipped to $16.93 in mid-March, and has been recovering. Fresh off the IPO, with DoD proliferated-orbit contracts as the catalyst thesis — this one requires patience.
National Security Spacecraft · Recent IPO · Golden Dome Defense · DoD Prime · High Volatility
👥 Who's watching: Defense technology growth funds, space economy ETFs. IPO lockup dynamics add near-term volatility risk.
Firefly Aerospace (FLY) is a space and defense technology company with launch vehicles and spacecraft solutions for national security and commercial missions. It surged with the SpaceX IPO buzz wave in late March 2026. The company moved markets after-the-bell on March 19th per CNBC's biggest movers. The catalyst thesis is straightforward: any validation of the commercial launch market lifts all launch vehicles. Watch for DoD contract announcements as the primary fundamental driver.
Telesat (TSAT) is one of the largest global satellite operators, with a GEO fleet and its planned Telesat Lightspeed LEO network. The first Lightspeed satellite launch is scheduled for December 2026 — that's the binary event. At $35.50 and $509M market cap, Telesat is undervalued relative to the LEO buildout timeline if Lightspeed executes on schedule. The key risk: financing and timeline slippage have historically plagued legacy GEO operators making the LEO transition.
FLY: Launch Vehicles · DoD Defense · SpaceX Sentiment · FLY | TSAT: LEO Network · GEO Revenue · Lightspeed Catalyst · December 2026
🚀 ORBITAL ECONOMY — THEME HOT TAKE
There's a difference between trading SpaceX IPO sentiment and owning the structural orbit story. LUNR is the only name here with a locked-in government revenue stream large enough to justify the valuation thesis independently of speculative hype. ASTS is the lottery ticket — the TAM is real, but the execution window is long and the dilution risk is real. YSS and FLY are too new to size aggressively. TSAT is the sleeper nobody's talking about with a December 2026 launch as the trigger.
Theme 03 · 2 Tickers
🛡️ Autonomous Defense
Two names. One fights kinetic threats with autonomous drones. The other fights digital threats with AI-native security architecture. Both are compounding on government contract wins and both are deeply misunderstood by the broader market. These are the quiet compounders this newsletter was built to surface.
Ondas rebranded from "Ondas Holdings" in January 2026 — a signal of the company's identity shift from niche SDR provider to full-spectrum autonomous systems prime. The growth metrics are staggering: Q4 2025 revenue of $30.1M represented ~605% year-over-year growth. The company raised ~$960M net in January 2026 and ended 2025 with $594M cash. 2026 revenue guidance raised to at least $375M. Recent M&A has been aggressive: acquisitions include UK-based Rotron Aerospace (long-endurance VTOL drones), INDO Earth Moving Ltd. (awarded $140M military heavy engineering tender), and a joint venture with Heidelberg for autonomous drone defense in Germany and Ukraine. Ondas also formed a strategic AI-ISR partnership with Palantir and World View to build a multi-domain intelligence platform. This is a company that is building a systems-of-systems defense contractor in real time.
Autonomous Drones · Counter-UAS · Palantir Partnership · Military M&A · $375M Guidance
👥 Who's watching: Defense-focused growth investors, autonomous systems thematic funds, and anyone running a "future of warfare" thesis. The Palantir co-venture is a significant institutional signal.
VERDICT
The valuation is the debate — at $4B market cap with a still-unprofitable balance sheet, you're pricing in a lot of execution. But the strategic positioning is genuinely differentiated. The Palantir alignment is the strongest institutional endorsement this company has ever received. This is a high-risk, asymmetric position for aggressive growth portfolios.
Netskope delivered the first full year of positive free cash flow in FY2026 — Q4 ARR grew 31% YoY to $811M, Q4 revenue rose 32% to $196.3M, FY2026 total revenue hit $709M. The company launched four new AI security products with transaction-based pricing, broadening its platform to 25 products. More than 30 Fortune 100 companies trust Netskope One's Zero Trust Engine. The problem: the market punished it. Shares fell 11.83% the day after the Q4 report. Current price around $9 vs. a 52-week high near $28 — this is a beaten-down cybersecurity name with real fundamentals. 16 analysts average a "Buy" with a 12-month target that implies over 100% upside. FY2027 guidance implies continued operating losses, which is causing hesitation.
SASE Architecture · Zero Trust · AI Security · 31% ARR Growth · Contrarian Buy Candidate
👥 Who's watching: Contrarian growth fund managers and cybersecurity thematic investors looking at beaten-down IPO names with improving unit economics. Lock-up expiry on ~390M shares is the near-term overhang.
🔥 HOT TAKE
The market is pricing Netskope like it's broken. It isn't. It just delivered first-ever positive FCF with a 31% ARR grower and Fortune 100 penetration. If the lock-up overhang clears and FY2027 shows margin progress, this could be the most asymmetric risk/reward in cybersecurity right now.
Theme 04 · 1 Ticker
💊 RAS Oncology Breakout
RAS/MAPK mutations drive approximately 30% of all human cancers. For decades, this pathway was considered "undruggable." That is rapidly changing — and one company has assembled what may be the deepest pan-RAS pipeline in clinical-stage biotech.
Erasca went from $1 to a 52-week high of $16.40 in 12 months. The fuel: a deepening clinical pipeline with two major read-throughs imminent. ERAS-0015 (pan-RAS molecular glue) Phase 1 monotherapy data is expected H1 2026. ERAS-4001 (pan-KRAS inhibitor) Phase 1 data expected H2 2026. In January, the company closed a $258.8M upsized public offering at $10/share — funded into 2028. Worldwide rights for ERAS-0015 including China secured through option exercise with Joyo. U.S. composition patents covering both lead candidates were issued, extending protection through at least 2043. JPMorgan raised the price target to $25. Eight analysts rate ERAS a Buy. Bank of America is the lone sell-side dissenter. The HERKULES-3 trial reached completion — ERAS-007 read-through data is the next near-term catalyst.
Pan-RAS Pipeline · KRAS Inhibitor · Phase 1 Data H1 2026 · JPMorgan $25 Target · 2043 Patent Protection
👥 Who's watching: Precision oncology-focused biotech funds, long-only clinical-stage specialists, and anyone who has a KRAS thesis (this pipeline is the most modality-diverse in the space).
VERDICT
This is a binary event play with a meaningful data window in H1 2026. The $434M pro-forma cash provides a funded runway into H2 2028 — meaning even a delayed data read doesn't immediately kill the story. The worldwide rights expansion signals management confidence in ERAS-0015's efficacy signal. For biotech risk tolerances, this is among the most interesting pipelines in oncology right now.
Theme 05 · 4 Tickers
⚗️ Commodity Rotation
Not every scanner hit is a tech moonshot. This group of four names represents macro-driven commodity and cyclical rotation — names where geopolitical disruption, infrastructure demand, and price dislocations are creating real near-term volume. One of these we rate Avoid. The other three have distinct catalysts worth understanding.
Methanex is the world's largest methanol producer — and the market just woke up to a supply-side squeeze. Geopolitical tensions tightened global methanol supply in Q1 2026, with spot prices rising in both Asia and Europe. Jefferies raised their price target to $60 (from $50) and BMO Capital raised to $70 (from $65), expecting elevated prices to last several months. RBC Capital maintained Outperform at $55. The stock is up ~30% YTD. Q4 2025 adjusted EBITDA was $186M on production of 2.36M tonnes. 2026 guidance: 9.0M tonnes of methanol production. CEO Rich Sumner called 2025 "a year of significant achievement" while focusing on deleveraging the company's $3.7B debt load. Methanol's use in marine fuel, formaldehyde, and plastic feedstocks gives it structural industrial demand — not just energy speculation.
Methanol Supply Crunch · Geopolitical Premium · Industrial Commodity · Multiple Price Target Raises · Deleveraging
👥 Who's watching: Commodity rotation traders, value funds with materials exposure, and macro investors playing the geopolitical supply-disruption thesis.
CAR hit $190+ on April 1st — up 18.62% in a single session as TSA airport disruptions sent rental car demand surging across major US hubs. The 52-week range is $62.17–$212.81, illustrating the high-volatility nature of this name. Q4 2025 results were a broad miss — $2.66B revenue vs. $2.75B Street, third consecutive year missing consensus. But the event-driven pop is real: when air travel stumbles, rental car demand spikes. This is a short-duration tactical trade around travel disruption — not a long-hold thesis. The company recently filed to sell up to 5 million new shares, raising dilution concerns. Wall Street analysts have price targets ranging from $85 to $128 on the Street — with current price above $190, CAR is trading well above consensus right now.
Travel Disruption Play · Event-Driven · High Volatility · Dilution Risk · Short Duration
⚠️ Risk Flag: Trading above the highest Street price target. This is a momentum trade, not a value entry. Dilution risk from the new share offering and three consecutive earnings misses make this a high-risk hold at current prices.
RGC appeared on the scanner with 7 frequency hits — but our analysis rates this one Avoid. Current price around $36.50 with the average analyst price target at $14.02, implying a -61% downside to consensus. The highest analyst target on the Street is $16.95. This is a small-cap clinical-stage biotech with significant valuation disconnect from fundamental analysis. Technical signals show 6 Buy vs 5 Sell indicators — mixed. Volatility is extreme (24.58%). The market cap situation doesn't justify current pricing based on available pipeline data. This is a hot stock scanner hit — not a fundamental opportunity. Flag it, don't buy it.
High Volatility · -61% Analyst Downside · Small Cap · Speculative · Scanner Artifact
⚠️ Avoid: Every analyst target implies significant downside from current price. When scanner volume is the only bull thesis, that's a sell signal, not a buy signal.
🌐 BIG PICTURE — MACRO SYNTHESIS
What The Scanner Is Actually Telling You
Five separate macro theses landed on the scanner simultaneously in a 30-day window. That's not random. It reflects the current market's bifurcated structure: AI infrastructure is compounding on concrete capex commitments, the orbital economy is being pulled forward by geopolitics and government spending, and autonomous defense is moving from concept to procurement.
The commodity cluster (MEOH, CAR) is a reminder that macro disruption creates short-term dislocation trades — and those can be valuable even if the underlying business isn't growing structurally. The oncology name (ERAS) is the pure-binary bet — pipeline data determines everything.
The thread connecting it all: capital is following certainty. Photonics has NVIDIA contracts. Space has NASA contracts. Drones have DoD contracts. Biotech has patents. Even commodities have geopolitical certainty. In a volatile macro environment, the market is rewarding conviction-backed catalysts over hope-driven speculation.
📬 Never Miss an Issue
The Heat Sheet drops every Monday.
Volume leaders · Unusual options flow · AI-powered deep analysis. Free, forever.
Free plan available · See plans
Run your own analysis on any of these names
Share This Issue
STOCKARKALYTICS
Disclaimer: This publication is by StockArkalytics.com for informational and educational purposes only. Nothing constitutes investment advice, a solicitation, or a recommendation to buy or sell any security. All investments carry risk, including total loss of principal. Past performance is not indicative of future results. Always conduct your own due diligence or consult a licensed financial advisor.
© 2026 StockArkalytics.com · All rights reserved · Terms · Privacy · Disclosure · Read The Market Pulse Blog